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Aging remains the most pervasive risk factor for a wide range of chronic diseases that afflict modern societies. In the
United States alone, incidence of age-related diseases (e.g., cardiovascular disease, stroke, Alzheimer’s disease,
vascular cognitive impairment and dementia, cancer, hypertension, type-2 diabetes, chronic obstructive pulmonary
disease, and osteoarthritis) is on the rise, posing an unsustainable socioeconomic burden even for the most developed
countries. Tackling each and every age-related disease alone is proving to be costly and ineffective. The emerging
field of geroscience has posed itself as an interdisciplinary approach that aims to understand the relationship between
the biology of aging and the pathophysiology of chronic age-related diseases. According to the geroscience concept,
aging is the single major risk factor that underlies several age-related chronic diseases, and manipulation of cellular
and systemic aging processes can delay the manifestation and/or severity of these age-related chronic pathologies.
The goal of this endeavor is to achieve health improvements by preventing/delaying the pathogenesis of several age-
related diseases simultaneously in the elderly population by targeting key cellular and molecular processes of aging
instead of managing diseases of aging as they arise individually. In this review, we discuss recent advances in the
field of geroscience, highlighting their implications for potential future therapeutic targets and the associated
scientific challenges and opportunities that lay ahead.
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Introduction
The western world is aging at a historically unprecedented rate, and in the 21st century, we
will experience the most dramatic aging demographic shift in human history. Scientific
advances of the past decades have allowed for an impressive extension of lifespan in
industrialized nations. For example, the overall life expectancy at birth is ∼80.2 years (males:
77.4 years; females: 83.2 years) in the European Union. Combined with the decreasing birth
rates, this results in a dramatic shift in the age structure of several Western societies (e.g., in
Germany, Italy, Japan, as well as Hungary), which are predicted to have profound
consequences on a broad range of economic, social, and political scenarios. There are
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growing concerns about the long-term viability of the currently existing social support
systems, which are crucial for the well-being of the older generations.
The prevailing medical strategy for reducing the societal and healthcare impact of
population aging is to increase disease-free survival (“health span”), by delaying the develop-
ment of chronic age-related diseases (e.g., cardiovascular disease, stroke, Alzheimer’s disease,
vascular cognitive impairment and dementia, cancer, hypertension, type-2 diabetes, chronic
obstructive pulmonary disease, and osteoarthritis) and disability/institutionalization until a brief
period at the end of life. The recently established field within aging research, termed
“Geroscience,” is focused on extension of health span (52). Geroscience aims to bridge two
communities within the biogerontological research landscape. Traditionally, biogerontologists
focus on studying the basic mechanisms underlying aging (e.g., studying Caenorhabditis
elegans), whereas geriatricians seek to understand how to better the quality of life of our elder
population. Using the geroscience approach, these two disciplines are merged attempting to
better understand the bidirectional relationship between aging and age-related diseases. Aging
is a complex and multifaceted process, and it is now understood that many cellular and
molecular aging processes contribute to organismal aging. Thus, in theory, many potential
points of intervention are targetable to slow aging; delaying age-related decline in organ
functions; and decreasing the propensity for chronic diseases, disability, and mortality.
Current preclinical efforts to increase health span center on interfering with fundamental
cellular and molecular processes of aging, such as heightened state of inflammation, increased
oxidative stress, cellular senescence, mitochondrial dysregulation and cellular energetic
dysfunction, impaired proteostasis, endocrine dysfunction, and reduced cellular and organismal
stress resistance. In the past decade, growing understanding of cellular and molecular
mechanism of aging in model organisms and then in laboratory rodents and non-human
primates has allowed the scientific community to design and evaluate novel interventions
[e.g., metformin (6, 29) and rapamycin (10, 15, 22, 32, 34, 35, 39, 49)] aimed to interfere with
key aging processes in humans as well, increasing disease-free survival. In this mini-review, we
provide an update on recent geroscience research using a variety of experimental approaches,
providing novel insights to elucidate common cellular and molecular pathways by which aging
contribute to the pathogenesis of a vast array of age-related diseases.
Recent Advances in Geroscience
Research of fundamental, underlying mechanisms that drive the relationship between aging
as a risk factor and chronic age-related pathologies is being conducted in multiple academic
disciplines, including cellular biology and physiology, endocrinology, genetics, cognitive
studies, molecular biology, metabolic biochemistry, molecular mechanisms that drive
longevity, neurobiology, hypertension research, frailty research, immunology, cancer biolo-
gy, Alzheimer’s research, vascular biology, muscle and exercise physiology, and cerebro-
vascular and stroke research.
As expected, widespread age-related structural and functional changes across the whole
network of an aging biological system will contribute to the pathogenesis of a plethora of
diseases and disorders of multiple organs associated with old age including diseases of the
heart, brain, eye, kidney, and the musculoskeletal system (16, 17, 23, 27). The present
overview intends to highlight selected important current and emerging research directions in
the field of geroscience research with the objective to facilitate prevention or the development
of therapeutic treatments for age-related chronic diseases.
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Advances in insulin and growth hormone/insulin-like growth factor 1 (GH/IGF-1) signaling
An important evolutionarily conserved mechanism of aging involves dysregulation of IGF-1
signaling (4, 7, 14, 63). Extant studies have previously demonstrated that age-related decline
in IGF-1 levels contributes significantly to brain (53) and cardiovascular aging (60, 63, 68).
More recent evidence suggests that IGF-1 has sexually dimorphic, pleiotropic, and time-
dependent effects on health span, pathology, and lifespan (4, 7, 14, 55, 63). Further studies
are warranted to better understand the distinct roles of GH and IGF-1 signaling, the role of
developmental effects of GH and IGF-1 in regulation of lifespan and health span (55), and the
differential effects of circulating and paracrine IGF-1.
Advances in genetics and epigenetics of aging
New insights into genetic and epigenetic mechanisms in the aging process have the potential
to offer new strategies and directions for discovery of new biomarkers and therapeutic
interventions. Recent studies demonstrate that DNAmethylation age is an accurate biomarker
of chronological age and predicts lifespan (33, 36). A recent genome-wide association study
indicated a critical role for human telomerase reverse transcriptase in regulating the
epigenetic clock, in addition to its established role of compensating for cell replication-
dependent telomere shortening (36). Recent studies have also identified DNA methylation as
a potential mediator of age-related diabetes risk (20, 75) as well as playing a role in preserving
cellular memory (11).
Another important area of geroscience research focuses on the role of interaction of the
two mitochondrial genetic systems, including alterations in the mitochondrial DNA and
dysregulation of the nuclear DNA-encoded mitochondrial genes, in the process of aging
and the etiology of common age-related metabolic and degenerative diseases and cancer
(37, 80).
Advances in the role of dysregulation of immune responses and exacerbated sterile
inflammation in aging
As humans age, potentially detrimental changes occur in the immune system (48). For
example, there is evidence from many studies that people aged over 65 years are more
susceptible to infectious diseases. Novel findings suggest that chronic infection with human
cytomegalovirus (CMV) might be altering the balance of immune responses in aging. This is
of particular interest to the geroscience community, since over 90% of adults 80 years of age
or older exhibit persistent infection with CMV (1, 24, 31, 44, 54), which replicates in the
vascular endothelial cells and may contribute to a number of multiorgan age-related
microvascular pathologies.
Aging is also associated with chronic low-grade sterile inflammation that has been
termed “inflamm-aging.” It is well accepted that this pro-inflammatory state is an important
contributing factor to the development of a wide range of age-related diseases, including
atherosclerosis and osteoarthritis (16, 17, 27). Osteoarthritis is a chronic, painful inflamma-
tory joint disease that affects approximately 40% of adults over 70 years. There is growing
evidence that synergistic interaction of aging and lifestyle factors that promote chronic
inflammation, such as obesity, significantly increases the risk for osteoarthritis (27). Recent
studies have identified mechanisms contributing to osteoarthritis progression in aging and
obesity including increased innate immune responses, macrophage activation, and pro-
inflammatory cytokine production (27). Synergistic interaction of aging and obesity was also
shown to promote vascular inflammation and dysfunction in aging (70, 71, 78).
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Advances in cellular senescence
Extant evidence shows that during aging, the increased DNA damage contributes to the
growing number senescent cells in the tissues. Senescent cells express a pro-oxidative,
pro-inflammatory phenotype called the senescence-associated secretory phenotype. In recent
years, the concept has emerged that presence of senescent cells contributes to the pathogen-
esis of a wide range of age-related inflammatory diseases (25, 81), such as osteoarthritis (26)
and atherosclerosis (9). Recent breakthrough studies demonstrate that transplanting relatively
small numbers of senescent cells into young mice is sufficient to cause persistent aging-like
physical dysfunction, induce spreading of cellular senescence to the host tissues and to reduce
survival (83, 85), indicating the potency of senescent cells in shortening health- and lifespan.
It is expected that new studies will lead to a better understanding of the molecular
mechanisms underlying the activation of senescence pathways (12, 42, 51). This knowledge
will enable the development of novel treatments aimed at removing the senescent cellular
burden to increase health span by delaying/preventing age-associated pathologies (26, 46).
Advances in mTOR signaling
There is growing evidence suggesting that inhibition of the evolutionarily conserved
mammalian target of rapamycin (mTOR, also known as mechanistic target of rapamycin)
pathway may have protective effects against aging (3, 22). Novel findings have identified that
the mTOR pathway plays an integral role in the coordination of metabolism, protein
synthesis, cell growth, and inflammation whereby mTOR regulates cellular stress resistance,
modulates aging processes, and determines mammalian lifespan (3, 30, 66, 77). Inhibition of
mTOR was shown to exert multifaceted anti-aging effects in multiple organ systems,
including significant vasoprotective effects, protecting endothelial function (34, 35) and the
blood–brain barrier (BBB) in models of Alzheimer’s disease and vascular cognitive
impairment (79).
Advances in cardiovascular aging
Within the past decade, there has been a newfound interest in the study of the aging heart and
vasculature. New evidence suggests that in addition to promoting atherogenesis, aging
significantly impacts the structure and function of cells within the wall of microvessels as
well (72). Fully within the scope of the geroscience initiative, recent studies have indicated
that age-related alterations of the brain microcirculation can initiate the pathogenesis of a
spectrum of diseases ranging from vascular cognitive impairment to Alzheimer’s disease
(67, 72). The high energetic requirements of the brain’s neuronal activity must be closely
matched by an adequate supply of oxygen and nutrients. This is achieved by a physiological
homeostatic mechanism called neurovascular coupling. Unfortunately, this activity-
dependent increase of cerebral blood flow becomes compromised during aging (59). The
endothelium is an actively involved component of the neurovascular unit, which plays a
crucial role in propagation of vasodilation during functional hyperemia. NO released from the
cerebral microvascular endothelium is a critical vasodilator that regulates microvascular
resistance and thereby cerebral blood perfusion. Previous studies demonstrate that aging
leads to impairment of neurovascular coupling responses due to an age-related impairment of
NO bioavailability (59). It was recently shown using mice with genetic modulation of eNOS
expression and pharmacological inhibition of NO synthesis that microvascular NO release
plays a critical role in the mediation of neurovascular coupling responses, providing an
important theoretical framework fueling further research in cerebromicrovascular aging (59).
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Recent advances in the study of cellular and molecular processes underlying neurovascular
coupling has allowed for developing novel therapeutic strategies to restore microvascular
blood flow, rescue neurovascular responses, and thus improving cognition in older indivi-
duals (62, 64). Endothelial dysfunction is pervasive during vascular aging, thus it is likely that
interventional strategies that improve cerebral blood flow will exert beneficial effects on other
vascular beds as well in older individuals (62, 72). New developments in understanding the
contributions of altered microenvironment in the aged vascular wall (74) and the role of age-
related alteration in the extracellular matrix (19) will lead to the identification of new targets
to prevent diseases ranging from hemorrhagic stroke to aortic aneurysms.
BBB disruption is another important factor, which plays a key role in increased
neuroinflammation in the aging brain (58, 69, 73), likely contributing to the pathogenesis
of Alzheimer’s disease and vascular cognitive impairment (56, 57). There is newly found
evidence that impaired microvascular resilience to stressors exacerbates BBB disruption
induced by hypertension and metabolic diseases, which likely have direct relevance for
impaired synaptic function and cognitive decline (61, 69).
Recent advances in cardiac aging improved our understanding of the role of age-related
alteration in the extracellular matrix (38), bioenergetics, and stem cell biology. Recent studies
indicate that there might be striking similarity between human and canine aging processes
(76). Newfound data suggest that companion dogs may be a particularly useful animal model
for understanding mechanisms contributing to cardiovascular aging and for developing and
testing interventions to ameliorate age-related cardiovascular dysfunction.
Advances in brain injury and cognition in aging
Traumatic brain injury (TBI) and other brain-related injuries are a serious health problem that
can lead to long-lasting cognitive deficits in older individuals. In addition to its high mortality
(35%–40%), survivors are left with a broad spectrum of symptoms including short-term
memory problems, behavioral disabilities, and other health symptoms. Recent evidence
suggests that increased mitochondrial production of reactive oxygen species (ROS) in the
aged cerebral microvessels may contribute to the secondary damage to the brain following
the initial brain trauma. Future research should determine the efficacy of mitochondria-
targeted antioxidants (62) in aged preclinical models of TBI.
Advances in pharmacological therapies to delay aging
The gathering evidence on the mechanisms underlying age-related pathophysiological
alterations holds promise for the potential development of novel clinical diagnostic methods
and new therapeutic strategies. Despite recent advances in geroscience, the cellular, and
molecular mechanisms involved in the pathogenesis of age-related diseases are incompletely
understood. Studies aimed to test the effects of anti-aging intervention on a wide range of
basic cellular mechanisms of aging, and physiological functions of other organ systems are
underway and hold powerful opportunities to slow down the aging process. Examples of new
studies that have identified novel pathways and potential treatments include the demonstra-
tion of the role of increased mitochondrial production of ROS that critically contributes to the
genesis of microvascular endothelial dysfunction in older organisms (62). Treatment with the
recently discovered mitochondrial-targeted antioxidant peptide SS-31 was reported to rescue
microvascular endothelial function and neurovascular coupling responses, improving cogni-
tion in aged mice (62). In the upcoming years, progress is expected with the combined use of
dietary interventions (11) and supplements with anti-aging efficacy (41, 45). In the past few
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years, several therapeutic strategies have emerged to target senescent cells for delaying the
aging process and preventing the progression of chronic diseases (2, 5, 28, 65). Recent studies
have identified dasatinib plus quercetin (85), heat shock protein 90 (HSP90) inhibitors (18),
fisetin (86), mouse double minute 2 homolog antagonists (82) and agents acting on oxidation
resistance protein 1 (87), and B-cell lymphoma 2 (8) as a potential senolytic agents that could
extend health span and/or lifespan. Research efforts that identify novel gene targets, which
regulate aging processes in model organisms (30, 47), also provide a potentially valuable
approach for drug repurposing (13) to improve outcomes in elderly patients suffering from
age-related chronic diseases.
Summary
On the whole, thanks to recent important advances during the past couple of years, the field of
geroscience has enjoyed an explosive growth. The concept has been increasingly accepted
that by targeting fundamental aging processes, it may be possible to ameliorate a vast array of
human diseases associated with old age and is destined to revolutionize the way we think
about aging research (6, 28, 29, 43, 50, 84, 85, 88). Because we are just at the beginning of
this paradigm shift, further interdisciplinary studies are needed that bridge clinical research
and basic animal model research to learn more about the underlying mechanisms of aging.
Using the perspective of geroscience in novel models of aging and age-related diseases will
be rewarding. Important areas for future translational research in the field of geroscience
include modulation of the proteasome and autophagy pathways, identification of treatments
that restore cellular energetics, and development of novel dietary interventions to delay aging
(11, 21, 40). In geriatric medicine, frailty is an important problem. Frail older people exhibit
impaired stress resilience, prone to dependency, and have reduced life expectancy. The
geroscience approach to aging research will facilitate the understanding of aging processes
that compromise the function of multiple organ systems simultaneously and thereby
contributing to frailty, and will improve these health outcomes, decreasing demand for
medical and social care.
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